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at 42.18% compared to 25.91% of LLD (p < 0.0001). Bleeding,
readmission, and mortality were similar (p = NS). Risk-adjusted
logistic regression also found no evidence for better outcome 
in patients given HLD of clopidogrel. CONCLUSIONS: Using
time-stamp data, this large study retrospectively investigated
effects of HLD clopidogrel in usual care setting. Patients receiv-
ing HLD did not experience better outcome. If providers tend to
select HLD to treat high-risk patients in practice, an underlying
dose-outcome bias would exist in the data. It is unclear how
much of the bias is mitigated by higher dosing in the usual care
setting. More research is needed.
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OBJECTIVE: To review the existing evidence of the economic
impact of contrast echocardiography (CE) in the diagnosis and
management of patients with suspected or known coronary
artery disease (CAD). METHODS: A systematic search was
undertaken to identify studies that provided empirical evidence
of the cost-effectiveness of CE relative to an alternative diag-
nostic modality. Findings and study methodologies were
reviewed and suggestions for further research were offered.
RESULTS: Six studies were identiﬁed, including one conference
abstract and one unpublished study. In four studies of patients
with sub-optimal un-enhanced echocardiogaphic images, CE was
reported to reduce the average cost to obtain a diagnosis by
17–64% compared with a second-line nuclear imaging (SPECT)
test. However, these studies did not include the impact of poten-
tial differences in diagnostic accuracy between tests. A ﬁfth study
reported that compared with trans-oesophageal echocardiogra-
phy CE resulted in similar yield of accurate diagnoses at a sub-
stantial reduction in costs for determination of regional and
global ventricular function in ‘technically difﬁcult to image’
patients. In a sixth study in patients with an intermediate risk
for CAD, the average cost to identify CAD was lowest when
SPECT Tc-99m or CE ($267 and $355 per case detected, respec-
tively) and highest when exercise electrocardiography ($1320 per
case detected) was used as the ﬁrst-line test. CONCLUSIONS:
The results support the cost-effectiveness of CE compared with
nuclear imaging in patients with a sub-optimal un-enhanced
image, and potentially in other patient sub-groups such as those
with an intermediate risk of CAD. However, more comprehen-
sive economic analyses incorporating diagnostic accuracy and its
implications for patient management are required before these
results can be considered conclusive. More research is also
needed to assess the economic impact of myocardial contrast
echocardiography (MCE) in its wider applications in the man-
agement of CAD patients, such as the assessment of myocardial
viability.
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OBJECTIVES: The efﬁcacy of platelet inhibition with clopido-
grel for patients (pts) with non-ST-elevation acute coronary syn-
dromes was demonstrated in CURE and PCI-CURE trials. The
purpose of present analysis is to estimate the long-term cost-
effectiveness of clopidogrel in Poland, using clinical outcomes
and resource utilization from CURE and in PCI-CURE.
METHODS: Costs of hospitalizations and studied drugs were
calculated based on resource utilization collected in case report
form for all pts in CURE (clopidogrel, n = 6259, placebo, n =
6303) and in the subgroup of PCI-CURE pts (clopidogrel/n =
1313, placebo/n = 1345). Comedications were not included in
the economic analyses as drug utilization was similar in clopi-
dogrel and placebo group. Unit costs were calculated using drugs
retail prices and medical procedures tariffs contracted by
National Health Found. Because of lack of sufﬁcient Polish epi-
demiological data two different sources (Framingham and
Saskatchewan databases) were used to evaluate the lost life
expectancy associated with death, MI and stroke. A discount rate
of 3% was applied. Results are expressed in cost per Life Year
Saved. RESULTS: Total cost per pt was higher in the clopidogrel
arm for CURE and PCI-CURE (+€463 and +€454) respectively.
The estimated number of LYS with clopidogrel for CURE pts
was 69.9 per 1000pts treated using Framingham and 68.2 using
Saskatchewan data. Corresponding values for PCI-CURE were
69.8 per 1000 patients with Framingham and 88.5 with
Saskatchewan data. The cost per LYS for clopidogrel versus
placebo for CURE pts was €6624 with Framingham and €6789
with Saskatchewan database. For PCI-CURE pts these ﬁgures
were €6504 and €5130 respectively. CONCLUSION: Based on
the clinical ﬁndings of CURE and PCI-CURE trials clopidogrel
appears to be cost-effective in Poland. Although results obtained
from two different sources of survival data are consistent, the
interpretation of present ﬁndings requires further adjustment to
Polish epidemiological settings.
PCV33
A COST-EFFECTIVENESS ANALYSIS OF LOW-DOSE ASPIRIN
IN THE PRIMARY PREVENTION OF CARDIOVASCULAR
DISEASE IN FOUR EUROPEAN COUNTRIES
Lamotte M1,Annemans L1, Evers T2, Kubin M2
1IMS Health, Brussels, Belgium; 2Bayer Healthcare AG, Wuppertal,
Germany
OBJECTIVES: Low-dose Aspirin is standard care in patients
with cardiovascular disease (CVD). In primary prevention the
use of Aspirin is not fully established although meta-analyses and
guidelines support its use in persons at increased CVD risk. This
study assessed the health economic consequences of the use of
low-dose Aspirin in the primary prevention of CVD in the UK,
Germany, Spain and Italy. METHODS: Based on results reported
in two meta-analyses, a Markov model was developed to predict
the cost-effectiveness of Aspirin in the primary prevention of
CVD. Different time horizons (1 to 10 years), 1-year cycles and
direct costs from the health care payer’s perspective (2003) were
used. Effects were expressed in Life-Years (LY) and QALY. Utility
data (TTO) were obtained from published data. Country speciﬁc
discounting was applied. RESULTS: For patients with an annual
risk of coronary heart disease (CHD) of 1.5%, the model results
in average savings with low-dose aspirin after 10 years of €201
[95%CI €81–€331], €281 [95%CI €141–€422], €797 [95%CI
€301–€1331] and €427 [95%CI €122–731] per patient in the
UK, Germany, Spain and Italy, respectively. Although the savings
in the ﬁrst year are modest (on average €10-€20), from the
second year on they are signiﬁcant in all countries. Sensitivity
analysis showed the results robustness. The number of LY and
QALY gained with aspirin were respectively 0.2 and 0.4 years 
in the four countries. Monte Carlo analysis showed aspirin-
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dominance in ± 97% of cases for the three studied annual risks
of CHD (0.6%, 1.0% and 1.5%) except for Italy, where domi-
nance in ≥95% was seen at annual risks of 1% and 1.5%. CON-
CLUSIONS: Administering low-dose Aspirin to patients with an
annual risk of CHD of ≥1% is signiﬁcantly cost-saving from the
health care payer’s perspective in all countries analysed. Savings
start after one year of treatment.
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Nationale des Coûts”: National Study of Costs) database of
public sector. The PMSI (“Programme de Médicalisation des Sys-
tèmes d’Information”) is the French equivalent of DRG system.
The GHM (“Groupes Homogènes de Malades”: Homogeneous
Groups of Patients) corresponding to cardiovascular events were
determined from classifying medical procedure (CdAM: “Clas-
siﬁcation Des Actes Médicaux”) and/or from main diagnosis
(ICD 10: International Classiﬁcation of Diseases). The numbers
of hospitalizations were then determined. The most representa-
tive GHM were selected, and associated prices/costs have been
weighted by suitable numbers of hospitalizations in order to
obtain an average price/cost of hospitalization. RESULTS:
Average prices (private sector) and costs (public sector) have
been estimated respectively in private and public sector at €1815
and €1315 for a coronarography, €2704 and €2971 for a coro-
nary angioplasty (€5750 and €5178 with stenting), €14,905 and
€13,119 for an aorto-coronary bypass, €4271 and €4216 for a
myocardial infarction (including procedures), €2967 and €3483
for a cerebrovascular accident, €1799 et €2570 for a transient
ischemic attack, €1589 and €2350 for stable and unstable
angina, €2433 et €3658 for a heart failure. CONCLUSION: It
is difﬁcult to isolate speciﬁc hospital prices/costs of cardiovas-
cular events. Nevertheless those approximations seem to be the
only way to assess these prices/costs, which in addition are likely
to be used in pharmacoeconomic models.
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OBJECTIVES: To evaluate differences between public and
private hospitals in abciximab prescriptions for patients under-
going PCI with coronary artery disease (CAD) in France.
METHODS: Data were collected from the 2002 “PMSI” data-
base (DRG for every patient admitted). To evaluate the total
number of PCI performed for CAD in private and public hospi-
tals, we selected the following DRGs (myocardial infarction,
coronary endoprothesis, and cardiac catheterization) and crossed
them with the following acts performed during PCI (translumi-
nal angioplasty, stent implantation, atherectomy). We computed
the numbers of abciximab prescriptions from the French sales
2002 in each private and public hospitals. RESULTS: In 2002,
96,247 PCI were performed in patients hospitalized for CAD
(52,046 in private setting, 44,201 in public setting). Abciximab
was administered for 7719 and 2327 PCI procedures in public
and private hospitals, respectively. Abciximab was used for only
18% of PCI in public hospitals and 4.5% in private ones,
although, abciximab is the only drug indicated for prevention of
cardiac ischemic complications in patients undergoing PCI and
recognized by French authorities as correlated to a “major
improvement” for these patients. CONCLUSION: The impor-
tant difference in 2002 between public and private sectors can
be mostly explained by different funding systems: global budget
for public hospitals, fee for services, payment per day and low
daily ﬁxed fare for drugs in private hospitals. In France, a new
DRG system of funding, close to the one for proﬁt hospitals was
implemented in public institutions in 2004. Before that, the
results show a clear difference in the recourse to abciximab
between public and private sectors for the same DRGs due to
the difference in ﬁnancing. If nothing happens, it can be foreseen
that the results observed for proﬁt hospitals will be the rule for
public hospitals and patients undergoing PCI could no more
beneﬁt from abciximab.
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OBJECTIVES: This French DRG analysis aimed to obtain esti-
mations of numbers and prices/costs of private and public 
hospitalizations in 2002 for following cardiovascular events:
coronarography, coronary angioplasty, aorto-coronary bypass,
myocardial infarction, cerebrovascular accident, transient
ischemic attack, stable and unstable angina, heart failure.
METHODS: Anonymized databases were used: private and
public PMSI 2002 databases of BAQIMEHP (“Bureau Assurance
Qualité de l’Information Médico-Economique de l’Hospitalisa-
tion Privée”: Quality Assurance Committee of Health Economic
Information of Private Hospitalization) and ENC 2004 (“Etude
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